Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM23Y6K)

Drug Name
LYS228 Drug Info
Synonyms
1810051-96-7 (free acid); 1-((((Z)-1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopropane-1-carboxylic acid; SCHEMBL17094584; 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid; l-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid
Indication
Disease Entry ICD 11 Status REF
Urinary tract infection GC08 Phase 2 [1]
Cross-matching ID
PubChem CID
118380292
TTD Drug ID
DM23Y6K

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Bacterial Penicillin binding protein 3 (Bact mrcA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Aztreonam DMDNJHG Bacterial infection 1A00-1C4Z Approved [3]
Cefmetazole DM42W1B Bacterial infection 1A00-1C4Z Approved [4]
Cefotiam DMF5HU6 Respiratory tract infection CA45 Approved [5]
Latamoxef DMANL0D Bacterial infection 1A00-1C4Z Approved [4]
Mezlocillin DMY5JEP Acute gonococcal cervicitis Approved [6]
Moxalactam Disodium DMYKUNR Bacterial infection 1A00-1C4Z Approved [7]
Cefmenoxime DMPLY7B Bacterial infection 1A00-1C4Z Approved [8]
Benzylpenicillin DMS9503 Actinomycosis Phase 3 [9]
Cephalosporin C DMYW3ZG Discovery agent N.A. Investigative [10]
PCNOTAXIME GROUP DMGS6YH Discovery agent N.A. Investigative [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial Penicillin binding protein 3 (Bact mrcA) TT85JMW FTSI_ECOLI Binder [2]

References

1 ClinicalTrials.gov (NCT03377426) LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection (cUTI). U.S. National Institutes of Health.
2 Mode of Action of the Monobactam LYS228 and Mechanisms Decreasing In Vitro Susceptibility in Escherichia coli and Klebsiella pneumoniae. Antimicrob Agents Chemother. 2018 Sep 24;62(10):e01200-18.
3 Penicillin-binding protein PBP2 of Escherichia coli localizes preferentially in the lateral wall and at mid-cell in comparison with the old cell pole. Mol Microbiol. 2003 Jan;47(2):539-47.
4 Clinical relevance of antibiotic-induced endotoxin release in patients undergoing hepatic resection. World J Surg. 1999 Jan;23(1):75-9.
5 Genetic analyses of beta-lactamase negative ampicillin-resistant strains of Haemophilus influenzae isolated in Okinawa, Japan. Jpn J Infect Dis. 2006 Feb;59(1):36-41.
6 Bactericidal effect of piperacillin alone and combined. Presse Med. 1986 Dec 20;15(46):2297-302.
7 Moxalactam (6059-S), a new 1-oxa-beta-lactam: binding affinity for penicillin-binding proteins of Escherichia coli K-12.
8 In vitro evaluation of E1040, a new cephalosporin with potent antipseudomonal activity. Antimicrob Agents Chemother. 1988 May;32(5):693-701.
9 Association of amino acid substitutions in penicillin-binding protein 3 with beta-lactam resistance in beta-lactamase-negative ampicillin-resistant Haemophilus influenzae. Antimicrob Agents Chemother. 2001 Jun;45(6):1693-9.
10 DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
11 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.